Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALECSAT versus Avastin + irinotecan in relapsed glioblastoma multiforme
2013-003045-42Phase 2Completed
- Sponsor
- CytoVac
- Start
- Oct 2013
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of alecsat in glioblastoma (GBM) (2 arms), sponsored by CytoVac. Primary endpoint: Progression-free survival. Started Oct 2013; status: completed.
02
Drugs
alecsat
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2013-003045-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003045-42.